Objectives-To study prevalence and incidence of diabetes mellitus in patients with cystic fibrosis.
Introduction
In the past three decades survival of patients with cystic fibrosis has steadily improved to a median of about 30 years in several centres.'-5 Following the increased life expectancy, glucose intolerance has been observed with increasing frequency in these patients." We conducted a five year prospective study of glucose tolerance in a large unselected group of patients with cystic fibrosis in order to define the incidence ofdiabetes mellitus in cystic fibrosis. Measurement of glycated haemoglobin has been suggested as an alternative to the oral glucose tolerance test for assessing glucose metabolism, and serial testing of parameters of glycaemic control has been suggested for diagnosing diabetes and predicting progression to diabetes in high risk groups (such as subjects with impaired glucose tolerance,9 Pima Indians,'0 pregnant women,"' patients with chronic pancreatitis,"2 and patients with cystic fibrosis"3 14) . We therefore annually measured glycated haemoglobin concentrations as well as performing oral glucose tolerance tests to test whether screening with this parameter could identify cystic fibrosis patients with undiagnosed diabetes. We also studied whether impaired glucose tolerance was a risk marker for the development of diabetes in such patients. Finally, we studied whether those patients who had normal glucose tolerance at all five oral glucose tolerance tests had stable plasma glucose concentrations after fasting and glucose loading and stable glycated haemoglobin levels.
Subjects and methods
During 1989, 245 patients attended our cystic fibrosis centre. The diagnosis of cystic fibrosis was based on the presence of abnormal electrolyte concentrations in sweat and a typical clinical picture. 15 16 We included all 226 patients aged over 2 years in our five year prospective study 
13-90/)) (P<0-00001).

Discussion
In our study the patients had a median age of 13-6 years, and during the study the prevalence of glucose intolerance (impaired tolerance and tolerance indicating diabetes) increased from 27% to 42% and the prevalence ofdiabetes had increased from 11% to 24%. The annual incidence of diabetes was relatively constant, averaging 3-8% a year in the total population, and increased with age: 5'0% a year in patients aged 10 or more and 9-3% a year in patients aged 20 There is evidence, however, that the overall clinical status deteriorates gradually in diabetic'6 and prediabetic'6 patients with cystic fibrosis compared with non-diabetic patients and that insulin treatment of diabetic patients improves lung function and reduces the number of lung infections with Haemophilus influenzae and Streptococcus pneumoniae.27 Moreover, diabetic patients with cystic fibrosis are probably no less prone to developing late diabetic complications than are patients with other types of diabetes of similar duration and glycaemic control.6 It is therefore important to diagnose and treat diabetes in patients with cystic fibrosis and to identify those patients at risk of developing diabetes.
IDENTIFICATION
Since diabetes in cystic fibrosis is often asymptomatic (67% of newly diagnosed patients in our study), it is often underdiagnosed. Thus, the reported prevalences of diabetes requiring insulin treatment of 4 1% and 5-2% in large groups ofAmerican (median age 12'5 years)5 and Canadian (mean age 17-3)2 cystic fibrosis patients were lower than would have been expected from our findings: prevalences of diabetes of 11% at entry (median age and 24% at exit (median age 17.3). Only 16% of our diabetic patients had abnormally high fasting plasma glucose concentrations ( 7-8 mmol/1)'8 and haemoglobin Alc levels (> 6-4%) at the time of diagnosis of diabetes. Regular oral glucose tolerance tests are therefore mandatory to diagnose diabetes. We suggest that annual oral glucose tolerance tests are started as part of clinical practice in cystic fibrosis patients over the age of 10, as our two patients who developed diabetes below this age both had frank symptoms of diabetes at onset.
Identifying cystic fibrosis patients who are at risk of diabetes is desirable. As in non-insulin dependent diabetes,9"6 impaired glucose tolerance seems to be a 30 -500/Q3537 The configuration of the islets is altered so that they exist in disorganised clusters separated by broad bands of fibrous tissue and fatty replacement and degeneration,6 3 which, together with impairment of blood supply, may contribute to the abnormal endocrine function. Since the discovery and cloning of the cystic fibrosis transmembrane regulator gene it has been possible to search for its expression at the mRNA and gene product levels in various tissues. Its mRNA is present in the centroacinar cells of the intercalated duct of the pancreas but not in the surrounding serous acini or in the islets of Langerhans.38 Correspondingly, the major mutation genotype in cystic fibrosis (bF508) affects the severity of the exocrine pancreatic insufficiency, whereas the endocrine pancreatic function is unrelated to Seventeen committees told us that it was not appropriate to apply to them for ethics approval for this study; the remainder needed some type of formal application. Thirteen committees did not have a specific application form but requested between one copy and 21 copies of the protocol. Of the 132 committees that used an application form, 118 had a unique form, ranging in length from two to 18 pages. In the former Northern region a single application was considered by a "lead" committee on behalf of the seven others. In the former South Western region an application followed a standard format but each committee considered it separately. Seventy six committees requested 10 or more copies of the completed application form and protocols. In all, we sent a total of 1095 protocols and 1116 application forms, together with a number of supporting documents. We estimated that, in total, this required seven to eight weeks of staff time. The cost of staff time, photocopying, and postage was estimated to be £4606, an average of £32 for each committee. This does not include the costs and time spent on additional telephone calls to clarify issues, responses to requests for additional information, and setting up and maintaining a database to record details of correspondence.
Three months after submitting applications to the 145 committees, 113 had responded. Eighty two expressed no objection to the study. Others raised a number of issues, including concerns about the aims of the study, its cost, confidentiality, consent, and the wording of the questionnaires and information sheets. Thirty one requested resubmission.
Comment
Seeking approval for a study covering a large geographical area is time consuming and expensive for both researchers and ethics committees. Researchers BMJ VOLUME 311
